Tohma, Yusuf Aytaç
Loading...

Profile URL
Name Variants
Y., Tohma
T.,Yusuf Aytaç
Y.A.Tohma
Aytac Tohma Y.
Tohma Y.
Yusuf Aytaç, Tohma
Y. A. Tohma
T., Yusuf Aytaç
Tohma, Y. Aytaç
Aytac Tohma, Yusuf
Tohma, Yusuf A.
Tohma, Yusuf Aytac
Tohma, Yusuf Aytaç
Y.,Tohma
Yusuf Aytac, Tohma
T.,Yusuf Aytac
Tohma, Y. A.
T., Yusuf Aytac
Tohma,Y.A.
T.,Yusuf Aytaç
Y.A.Tohma
Aytac Tohma Y.
Tohma Y.
Yusuf Aytaç, Tohma
Y. A. Tohma
T., Yusuf Aytaç
Tohma, Y. Aytaç
Aytac Tohma, Yusuf
Tohma, Yusuf A.
Tohma, Yusuf Aytac
Tohma, Yusuf Aytaç
Y.,Tohma
Yusuf Aytac, Tohma
T.,Yusuf Aytac
Tohma, Y. A.
T., Yusuf Aytac
Tohma,Y.A.
Job Title
Doçent Doktor
Email Address
aytac.tohma@atilim.edu.tr
Main Affiliation
Department of Medical Services and Techniques
Status
Website
ORCID ID
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
Sustainable Development Goals
1NO POVERTY
0
Research Products
2ZERO HUNGER
0
Research Products
3GOOD HEALTH AND WELL-BEING
2
Research Products
4QUALITY EDUCATION
0
Research Products
5GENDER EQUALITY
0
Research Products
6CLEAN WATER AND SANITATION
0
Research Products
7AFFORDABLE AND CLEAN ENERGY
0
Research Products
8DECENT WORK AND ECONOMIC GROWTH
0
Research Products
9INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
10REDUCED INEQUALITIES
0
Research Products
11SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
12RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
13CLIMATE ACTION
0
Research Products
14LIFE BELOW WATER
0
Research Products
15LIFE ON LAND
0
Research Products
16PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
17PARTNERSHIPS FOR THE GOALS
0
Research Products

Documents
51
Citations
391
h-index
11

This researcher does not have a WoS ID.

Scholarly Output
5
Articles
5
Views / Downloads
12/0
Supervised MSc Theses
0
Supervised PhD Theses
0
WoS Citation Count
11
Scopus Citation Count
15
Patents
0
Projects
0
WoS Citations per Publication
2.20
Scopus Citations per Publication
3.00
Open Access Source
3
Supervised Theses
0
| Journal | Count |
|---|---|
| Frontiers in Endocrinology | 2 |
| BMC Pregnancy and Childbirth | 1 |
| Journal of Assisted Reproduction and Genetics | 1 |
| Turkish Journal of Obstetrics and Gynecology | 1 |
Current Page: 1 / 1
Scopus Quartile Distribution
Competency Cloud

3 results
Scholarly Output Search Results
Now showing 1 - 3 of 3
Article Citation - WoS: 4Citation - Scopus: 5Individualized Luteal Phase Support in Frozen-Thawed Embryo Transfer After Intramuscular Progesterone Administration Might Rectify Live Birth Rate(Frontiers Media Sa, 2024) Boynukalin, Fazilet Kubra; Tohma, Yusuf Aytac; Yarkiner, Zalihe; Gultomruk, Meral; Bozdag, Gurkan; Ozkavukcu, Sinan; Demir, BerfuBackground: The serum P concentrations are suggested to have an impact on pregnancy outcome. However there is no consensus about the optimal progesterone cut-off during the luteal phase. Few studies evaluated the effectiveness of a "rescue protocol" for low serum P concentrations and most of these studies used vaginal progesterone administration. There is paucity of data on the effectiveness of rescue protocol using intramuscular progesterone (IM-P) in frozen-thawed embryo transfer (FET). Methods: This study is a retrospective cohort study included 637 single or double blastocyst FETs with artificially prepared endometrium receiving 100 mg IM progesterone (P) after incremental estrogen treatment. Serum P concentrations were evaluated using blood samples obtained 117-119 hours after the first IM-P administration and 21 +/- 2 hours after the last IM-P administration. Patients with serum P concentrations <20.6 ng/ml on the ET day were administrated 400 mg vaginal progesterone for rescue. Results: Demographic and cycle characteristics were similar between patients receiving rescue vaginal P (embryo transfer (ET)-day P concentration < 20.6 ng/ml) and patients who did not need rescue vaginal P (ET-day P concentration >= 20.6 ng/ml). Clinical pregnancy, miscarriage, and live birth rates were similar between two groups: 52.9%(45/85) vs 59.6%(326/552), p=0.287; 11.1%(5/45) vs 14.1%(46/326), p=0.583; and 47.1%(40/85) vs 50.7%(280/552), p=0.526, respectively. Logistic regression analysis revealed that the female age (p = 0.008, OR=0.942, 95% CI = 0.902-0.984) and embryo quality (ref: good quality for moderate: p=0.02, OR=0.469, 95% CI =0.269-0.760; for poor: p=0.013, OR= 0.269, 95% CI = 0.092-0.757) were independent variables for live birth. Following rescue protocol implementation, ET-day P concentration was not a significant predictor of live birth. Conclusions: Rescue vaginal P administration for low ET day serum P concentrations following IM-P yields comparable live birth rates.Article Citation - Scopus: 2Yapay Dondurulmuş-Çözdürülmüş Blastokist Transferi Yapılan Hastalarda Embriyo Transferi Günündeki Yüksek Serum Progesteron Düzeyleri: Tavan Etkisi Var Mı(Turkish Society of Obstetrics and Gynecology, 2024) Findikli, Necati; Demir, Berfu; Tohma, Yusuf Aytaç; Bozdag, Gurkan; Bahcecı, Mustafa; Dündar, Betül; Boynukalin, Fazilet KubraAmaç: Yapay dondurulmuş-çözünmüş blastosist transferi (FET) siklusu uygulanan hastalarda embriyo transfer gününde yüksek serum progesteron düzeylerinin gebelik sonuçları üzerindeki tavan etkisi olup olmadığını değerlendirmeyi amaçladık. Gereç ve Yöntemler: Bu çalışma yapay FET döngüsü uygulanan 595 hastayı içeren retrospektif bir kohort çalışmasıydı. Progesteron düzeylerine göre yüzdelik dilimleri değerlendirdiğimizde 40,6 ng/mL 90. yüzdeliğe, 23,9 ng/mL ise 50. yüzdeliğe karşılık geliyordu. Bu bulguya dayanarak progesteron düzeyi kesme noktasını <20 ng/mL, n=220 (%37,0); 20-40 ng/mL, n=312 (%52,4) ve ≥40 ng/mL, n=63 (%10,6) olarak belirledik. Birincil sonuç ölçüsü, klinik gebelik (CPR) ve canlı doğum oranı (LBR) olarak belirlendi. Bulgular: Blastokist morfolojisi olarak genişleme derecesi, trofoektoderm ve iç hücre kitle derecesi klinik gebelik ile istatistiksel olarak anlamlı düzeyde ilişkili olduğunu bulduk (hepsi için p<0,001) ve 20-40 ng/mL arasındaki progesteron düzeyinin ise daha yüksek CPR ile ilişkili olduğunu bulduk (p=0,043). Çok değişkenli analizde; CPR ile ilişkili faktörler yalnızca blastosist genişlemesi ve iç hücre kütle derecesi bağımsız ve anlamlı faktörlerdi [p=0,011, (odds oranı) OO=1,6, güven aralığı (GA) 95%=1,13-2,39 ve p=0,007, OO=1,65, GA 95%=1,14-2,39, sırasıyla]. Progesteron düzeyi ve trofoektoderm derecesi istatistiksel olarak anlamlı bulunmadı. Faktörler ile LBR arasındaki ilişkinin değerlendirilmesinde sadece blastokist genişleme derecesi 4’e eşit veya üzerinde ve trofektoderm derecesi A veya B istatistiksel olarak anlamlı LBR ile ilişkiliydi. Sonuç: Bu verilere göre yapay FET siklusu yapılan hastalarda embriyo transferi gününde serum P4 düzeyi 40 ng/mL’nin üzerinde ise kullanılan progesteron dozunun azaltılmasına gerek olmadığını düşündük.Article Serum Progesterone Variability on Embryo Transfer Day in Hormone Replacement Therapy Cycles Using Intramuscular Injections During Frozen Embryo Transfers(Springer/plenum Publishers, 2025) Boynukalin, Fazilet Kubra; Tohma, Yusuf Aytac; Demir, Berfu; Gultomruk, Meral; Polyzos, Nikolaos P.; Bahceci, Mustafa; Bozda, Gurkan; Bozdağ, GürkanPurpose To assess the intra-individual variability of serum progesterone (P) levels on embryo transfer (ET) day, when the same dose of intramuscular progesterone (IM-P) was used in two consecutive hormone replacement therapy (HRT) frozen embryo transfer (FET) cycles. Methods A total of 75 patients undergoing two consecutive HRT-FET cycles in one year performed at Bahceci Ankara IVF Center between November 2019 and February 2022 were retrospectively analyzed. Serum P levels were measured at the 117th-119th hours of support by a single laboratory. The two measurements of P levels performed on the day of the first and the second FET were compared to evaluate the intra-individual variability of serum P levels. Results Comparisons between the 1st and 2nd FET cycles revealed statistically significant intra-individual variation, with an average difference of -2.47 ng/mL (95% CI: -4.65 to -0.29, p = 0.027) between the two consecutive measurements. To assess their consistency, the limit of agreement was also tested with the Bland-Altman method, in which the mean difference (+ 1.96 x SD and -1.96 x SD) was -2.47 (16.1 and -21.1). Based on a previous study, the frequency of low P levels, as expressed by being > 20.6 ng/mL on ET day, was similar between the 1st and 2nd FET cycles (14.7% vs. 9.3%, p = 0.31). Notably, most patients had improved P levels in the second cycle if initially low, while decreases were rare among those with initially higher levels. Conclusion Serum P levels may vary within the same individual across FET cycles despite the use of the same dosage of IM-P. Increasing maternal age, high body mass index, and fluctuating estradiol levels on the day of ET were identified as risk factors contributing to this variability.

